Lixte closes $5.0M private placement of common stock, preferred and warrants

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Gross proceeds of $5.0M; $4.0M received at closing July 2, 2025; $1.0M due upon SEC registration effectiveness.
Offering includes 2,382,084 common shares (or pre-funded warrants), 3,573,130 Series B convertible preferred shares, and 6,355,214 common warrants exercisable at $1.00/share.
Series B preferred shares bear 8% cumulative non-compounding dividend, convertible 1:1, and grant holders two board seats.
Net proceeds to be used for general corporate purposes and working capital; Spartan Capital served as placement agent.
Post-offering, company believes stockholders' equity exceeds $2.5M and awaits Nasdaq compliance determination.

item 1.01item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.